

DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty have indicated that they do not have any relevant financial relationships with ineligible companies* to disclose and have indicated that their presentation or discussion will not include off-label or unapproved product usage.

Brynn K. Dredla, M.D.
Ravi Durvasula, M.D.
Leo G. Eisenstein, M.D.
Margaret Johnson, M.D.
Kathie-Ann Joseph, M.D.

Warren L. Kupin, M.D.
Louis Miller, M.D.
Pragnesh P. Parikh, M.D.
Michelle Pearlman, M.D.
Michael Phillips, M.D.

Arianne Teherani, M.D.
Benjamin Wang, M.D.
Sheri Weiser, M.D.

Jodie Barkin, M.D., faculty for this educational activity, is a consultant for AbbVie, Aimmune Therapeutics, CorEvitas, Exact Sciences, Immunovia and Medtronic. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

John Bilezikian, M.D., faculty for this educational activity, is a consultant for Abiogen, Ascendis, Amolyt, Amgen and Radius, and a speaker for Radius and Amgen. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Michael Blaha, M.D., faculty for this educational activity, is a consultant for Scene Health and Kowa; an adviser for Novartis, Novo Nordisk, Bayer, Merck, Amgen, Roche, AstraZeneca, Boehringer Ingelheim, Vectura and Agepha; and a speaker for Novo Nordisk. He receives grant and research support from the NIH, FDA, AHA, Bayer, Amgen and Novo Nordisk. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

William Chey, M.D., faculty for this educational activity, is a consultant for AbbVie, Ardelyx, Atmo, Biomerica, Gemelli, Ironwood, Nestle, QOL Medical, Phathom, Redhill, Salix/Valeant, Takeda and Vibrant, and receives grant and research support from Commonwealth Diagnostics International, QOL Medical and Salix/Valeant. He receives royalties and is a patent beneficiary of My Nutrition Health, Digital Manometry and Rectal Expulsion Device, and is a shareholder of Corprata, Dieta, Evinature, Food Marble, Kiwi Bioscience and Modify Health. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Gregory Poland, M.D., faculty for this educational activity, is a consultant for AiZtech, Emergent Biosolutions, GSK Pharm, Invivyd, Janssen GS, Merck, Moderna, Novavax, Sanofi, Syneos and Valneva, and an adviser for GlaxoSmithKline, Moderna, Novavax, Sanofi and Syneos. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

Douglas Riegert-Johnson, M.D., faculty for this educational activity, receives grant and research support from Exact Sciences. He has indicated that the presentation or discussion will not include off-label or unapproved product usage.

John F. Rubin, M.D., co-symposium director of this educational activity, indicated that he is a shareholder in AstraZeneca, GE Healthcare, Merck, and Bristol-Myers Squibb. All of the relevant financial relationships listed for this individual have been mitigated.

All of the relevant financial relationships listed for these individuals have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies to disclose.

**Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.*